Arcus Biosciences, Inc. (RCUS) Stock Grade

About Arcus Biosciences, Inc.'s fundamentals

Arcus Biosciences is a biotechnology company with a market capitalization of $2.6 billion that reported a net loss in its latest annual statement, resulting in a negative net margin of -142.9%. The company experienced a revenue decline of 4.3% year-over-year, indicating shrinking sales. As a pre-profitable biotech firm, traditional valuation metrics like P/E ratio and return on equity are not applicable, and the company does not pay a dividend. Investors should note that the company is currently unprofitable and burning cash as it develops its pipeline.